BioSpace News Archive

Florida Cancer Specialists & Research Institute clinicians and leaders shared the latest advances in oncology pharmacy operations and dispensing practices at the National Community Oncology Dispensing Association 2022 Spring Forum held last month in Atlanta.

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that management will participate in a fireside chat at the LifeSci Partners Immunology and Inflammation Symposium on Tuesday, May 10, 2022 at 3:30 p.m. ET.

Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended March 31, 2022.

Sen-Jam Pharmaceutical, an innovative life sciences company developing a portfolio of revolutionary anti-inflammatories by repurposing existing molecules for novel combination therapy, this week began enrolling patients into their Phase 2 Clinical Trial for their promising oral COVID therapeutic.

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2022 financial results on Monday, May 16th.

Rising prevalence of chronic diseases such as diabetes and obesity worldwide and increasing volumes of weight loss surgeries are some key factors driving Bariatric Surgery market revenue growth.

Increasing sample collection and transportation & storage activities and rising demand for compound management outsourcing services are some key factors supporting the global Compound Management market revenue growth.

Reports and Data has recently added a research report on Sodium Polystyrene Sulfonate Powder Market Size, Growth & Analysis, By Type (15g/bottle, 454g/bottle), By Application (Hospital, Specialty Clinic, Diagnostic Center), By Region, Forecast To 2027.

Global health services company Cigna Corporation reported strong first quarter 2022 results reflecting revenue and earnings growth across its businesses.

BioArctic AB announced that the US Patent and Trademark Office has granted a new drug substance patent for the antibody ABBV-0805, invented by BioArctic as a potential treatment of Parkinson’s disease.